Neurotez

Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.

Overview

Raised to Date: Raised: $255,718

Total Commitments ($USD)

Platform

Netcapital

Start Date

08/19/2019

Close Date

06/24/2021

Min. Goal

$10,000

Max. Goal

$500,000

Min. Investment

$2

Security Type

Equity - Common

Series

Series A

Funding Type

RegCF

Price Per Share

$2.00

Pre-Money Valuation

$21,959,058

Rolling Commitments ($USD)

Status
Funded
Reporting Date

06/30/2021

Days Remaining
Funded
% of Min. Goal

2,557%

% of Max. Goal

51%

Likelihood of Max
Funded
Avg. Daily Raise

$379

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Location

Bridgewater, New Jersey

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2C

Margin

High

Capital Intensity

High

Business Type

Growth

Neurotez, with a post-money valuation of $22.5 million, is raising funds on NetCapital. The company is developing a hormone replacement therapy named Memtin to treat Leptin deficiency in Alzheimer’s patients. The drug will help slow down the cognitive decline in Alzheimer’s patients and other forms of dementia. Neurotez is led by Nikolaos Tezapsidis as the President and CEO, and Wes Ashford as the Chief Medical Officer. The company has already raised $4.5 million in funding from the National Institute of Health, IRS, and New Jersey Commission of Science and Technology. The current crowdfunding round has a minimum goal of $10,000 and a maximum goal of $500,000, and the proceeds will be used for the various studies, clinical trials, manufacturing, personnel costs, and debt repayment. Neurotez has already received many rewards and recognitions and is backed by an excellent team of experts.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-317,211

$-134,154

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$7,533

$302

Accounts Receivable

$0

$0

Total Assets

$206,070

$221,123

Short-Term Debt

$40,162

$23,336

Long-Term Debt

$26,000

$20,000

Total Liabilities

$66,162

$43,336

Financials as of: 08/19/2019
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Neurotez 01/27/2023 Netcapital $45,272,228 $15,952 Equity - Common Funded RegCF
Neurotez 03/10/2022 StartEngine $44,870,036 $33,845 Equity - Common Funded RegCF
Neurotez 06/24/2021 Netcapital $21,959,058 $255,718 Equity - Common Funded RegCF
Neurotez 02/26/2018 Netcapital $24,544,690 $95,809 Equity - Common Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Analyst Report Analyst Report Methodology Article

Summary

Neurotez has been selected as a “Deal To Watch” by KingsCrowd. This distinction is reserved for deals selected into the top 10% of our deal diligence funnel. If you have questions regarding our deal diligence and selection methodology, please reach out to hello@kingscrowd.com.

Problem

The most common cause of dementia, Alzheimer’s Disease is a devastating disorder resulting in loss of memory and cognitive ability with age. The disease is progressive, meaning it only worsens with time, and to date there remains no cure. 

And the disease is not uncommon. In fact, “Alzheimer’s is the sixth leading cause of death in the United States. On average, a person with Alzheimer’s lives four to eight years after diagnosis.” It is estimated that 44 million people suffer from the disease worldwide, 5.5 million of those are in the U.S. alone. The majority of these individuals, around 5.3 million, are above age 65, but around 200,000 are younger and exhibit early-onset symptoms of the disease.

Again, the disease remains to be cured, but has been extensively studied by neuroscientists across the globe. One trademark of Alzheimer’s is the presence of tau deposits in the brain causing plaques and tangles to develop in the wiring of our neurons. Accordingly, a number of treatments have been developed in an attempt at targeting these deposits, though none have been successful in curing the disorder.

Solution

Neurotez offers a solution that attacks symptoms before the formation of these destructive plaques. The drug targets Leptin, a hormone with various metabolic effects. Leptin receptors litter the hippocampus, or the center for memory in the brain, often associated with the cognitive decline that remains a hallmark of Alzheimer’s Disease.

Interestingly, cognitive degeneration in Alzheimer’s patients is often closely related to Leptin levels. The protein is present at a decreased level in these individuals, making hormone replacement therapy via Memtin, the drug developed by the Neurotez team, a logical treatment option.

Clinical Milestones/Timeline

Memtin is still early in development and as the team begins to receive Series A funding, clinical trials are scheduled to begin. With three clinical trial phases (not including preclinical trials) preceding FDA approval, it can be conservatively estimated that it will take up to 10 years for Memtin to reach the market. 

And chances of making it to market alone are slim. At this point, the drug is still preclinical, making investment in the team risky, but rewarding, as it offers a chance to get in at the ground floor with a potentially revolutionary treatment for a disease that plagues millions of Americans.

 

The Team

President and CEO, Nikolaos Tezapsidis, holds a PhD in Biochemistry at the University of Sussex, UK. He has several years of experience in biomedical research and has repeatedly been recognized by the Alzheimer’s Association for his efforts in researching the disease.

Cheif Medical Officer, Wes Ashford, holds an MD and a PhD in Neuroscience from UCLA and has been published over 100 times for research in Alzheimer’s alone. In addition, he serves as the Senior Research Scientist at the Stanford/VA Aging Clinical Research Center and Alzheimer’s Center.

George Perry, Chief Science Officer, holds a PhD in Marine Biology from Scripps Institution of Oceanography. He has over 1000 publications relating to AD and serves as the Semmes Foundation Endowed Chair in Neurobiology at the University of Texas at San Antonio.

The rest of the Neurotez team boasts impressive resumes in either medicine or business, rounding out the depth of its collective industry and entrepreneurial experience.

Existing Therapeutics

Much of the existing drugs for the management of Alzheimer’s fall into the category of cognition-enhancing medications. Few drugs target the existing pathology, and none have targeted Leptin thus far. Donepezil (Aricept), for example, is approved to treat all stages of Alzheimer’s.

Aricept works to prevent the breakdown of acetylcholine in the brain leading to improvements in cognitive functioning, but it is by no means a cure for the disease. Rivastigmine (Exelon), used to treat mild to moderate Alzheimer’s, also attempts to improve the function of nerves cells using a similar mechanism

Again, no existing drug targets the Leptin hormone, a known deficiency in AD patients, making Memtin highly differentiated, though risky, as there is no clinical treatment by which to compare it.

Why We Like it

 

 

  • Deep Team: The large Neurotez team comes from a wide range of academic and industry backgrounds. Lead members’ extensive industry experience has been acknowledged by leading research institutions, as well as The Alzheimer’s Association. Collectively, the team grounds trust in the research and product, making up for the uncertainty that may come with a preclinical drug.

 

 

  • Novel Therapeutic Strategy: The majority of existing Alzheimer’s research and treatments target the pathology and cognitive symptoms of the disease. Specifically, the tau deposits that result in neurofibrillary tangles and cognitive impairments that come as the disease progresses. Yet the disease remains uncured. Neurotez takes a completely novel approach, targeting the disease before the plaques manifest. In addition, the team is targeting a proven deficiency in AD patients that has yet to be clinically targeted. 

 

 

The Rating: Deal To Watch

Neurotez is a Deal To Watch. Investing in a preclinical drug has its risks, but the science behind the pharmacology is sound. AD patients have proven leptin deficiencies, making hormone therapy a logical solution. In addition, the depth of the team grounds trust in the product. Not only do members have extensive backgrounds in biology and neuroscience as scientists and medical researchers, many of them have been recognized specifically for their contributions to Alzheimer’s research.

In addition, Alzheimer’s is a debilitating disease that affects millions of americans. Until a cure is discovered, the already large market will only continue to grow. Getting in at the ground floor of a novel therapy could prove to be incredibly rewarding.

This is not to say that an investment isn’t risky. As previously mentioned, with three clinical trial phases (not including preclinical trials) preceding FDA approval, it can be conservatively estimated that it will take up to 10 years for Memtin to reach the market.  

And chances of making it to market alone are slim. However, this approach is truly unique and heavily differentiated from any other drugs on the market. Until now, few research teams and therapeutic strategies have targeted anything outside of the tau pathology and cognitive symptoms associated with the disease.

Finally, one more immediate, optimistic, exit opportunity depends on preclinical trials. Since most of the big pharma players have moved away from developing their own drugs, they tend to acquire these teams with a mix of equity and licensing agreements, bringing them to market/distribution in just 2-3 years. A large buyout from one of these major players in the near future is not out of the question if preclinical trials go well.  

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Neurotez Inc. on NetCapital
$
Platform: Netcapital
Security Type: Equity - Common
Valuation: $21,959,058
Invest in a different round for this company? Use my investment date to determine which raise I invested in.

Follow company

Follow Neurotez Inc. on NetCapital
View on Netcapital (Closed)